It is well known that the microbiome undergoes cyclical diurnal rhythms. It has thus been hypothesized that meal timing may affect gut microbial composition, function, and host health. This review aims to examine the effects of time-restricted eating (TRE) and Ramadan fasting (RF) on the composition of the gut microbiota in animal and human studies. The associations between composition of microbiota and host metabolic parameters are also examined. A search was performed on the PubMed, Cochrane, Scopus, and Web of Science databases up to December 31, 2022. The search strategy was performed using the Medical Subject Heading (MeSH) terms “intermittent fasting” and “gastrointestinal microbiome” and the key words “Ramadan fasting” and “microbes.” Seven human studies (4 TRE and 3 RF) and 9 animal studies (7 TRE, 2 RF-like) were retrieved. TRE and RF in human studies lead to an increase in gut microbial community alpha-diversity. In animal studies (both TRE and RF-like), fasting is not associated with improved alpha-diversity, but enhancement of microbial fluctuation is observed, compared with high-fat diet ad libitum groups. Within Firmicutes and Bacteroidetes phyla, no specific direction of changes resulting from fasting are observed in both animals and human. After TRE or RF, a greater abundance of the Faecalibacterium genus is observed in human studies; changes in Lactobacillus abundance are found in animal studies; and increases in Akkermansia are seen both in humans and in animals fed a feed-pellet diet. Only 2 human studies show a beneficial correlation between microbiota changes and host metabolic (HDL cholesterol) or anthropometric parameters (body mass index). These findings support the importance of both regimens in improving the gut microbiota composition. However, based on results of animal studies, it can be suggested that diet remains the essential factor in forming the microbiota’s environment. PROSPERO registration no. CRD42021278918.
Seaweed is a promising source of anti-obesity agents, including polysaccharides, proteins, polyphenols, carotenoids, and n-3 long-chain polyunsaturated fatty acids. The anti-obesity effects of such compounds may be due to several mechanisms, including inhibition of lipid absorption and metabolism, effect on satiety, and inhibition of adipocyte differentiation. The aim of this study was to assess the evidence from human randomized controlled trials for the effects of seaweed on body-weight status as well as lipid and nonlipid parameters in adults with overweight and obesity. Four databases—Medline, Scopus, Web of Science, and Cochrane Library—were searched from December 2022 to June 2023 using the following key words: Seaweed OR fucoxanthin OR alginates OR fucoidans OR phlorotannin’s OR macroalgae OR marine algae AND obesity OR overweight OR BMI OR body mass index. Eleven interventional studies (10 parallel and 1 crossover) were extracted. Meta-analysis showed a significant effect, favoring the intervention group for BMI (body mass index) (standardized mean difference [SMD]: -0.40; 95% CI: -0.65 to -0.16 kg/m2; P = 0.0013) and percentage of fat mass (SMD: -1.48; 95% CI: -2.66% to -0.30%, P = 0.0138). The results were seen when refined or extracted brown seaweed (BMI) or only refined brown seaweed (% fat mass) were administered to participants for at least 8 weeks. Moreover, a significant overall effect of seaweed supplementation on total cholesterol (SMD: -7.72; 95% CI: -12.49 to -2.95 mg/dL; P = 0.0015) and low-density-lipoprotein cholesterol (SMD: -7.33; 95% CI: -11.64 to -3.02 mg/dL; P < 0.001) was noted. Any significant effects of seaweed on glucose metabolism were not shown. Edible seaweed supplementation shows potential for managing obesity and disorders of the blood lipid profile when administered to participants for at least 8 weeks. PROSPERO registration no. CRD42022378484 (www.crd.york.ac.uk/PROSPERO).
This study aims to investigate the effects of a high-fat, high-fructose (HF/HFr) diet on metabolic/endocrine dysregulations associated with letrozole (LET)-induced Polycystic Ovarian Syndrome (PCOS) in prepubertal female mice. Thirty-two prepubertal C57BL/6 mice were randomly divided into four groups of eight and implanted with LET or a placebo, with simultaneous administration of an HF/HFr/standard diet for five weeks. After sacrifice, the liver and blood were collected for selected biochemical analyses. The ovaries were taken for histopathological examination. The LET+HF/HFr group gained significantly more weight than the LET-treated mice. Both the LET+HF/HFr and the placebo-treated mice on the HF/HFr diet developed polycystic ovaries. Moreover the LET+HF/HFr group had significantly elevated testosterone levels, worsened lipid profile and indices of insulin sensitivity. In turn, the HF/HFr diet alone led to similar changes in the LET-treated group, except for the indices of insulin sensitivity. Hepatic steatosis also occurred in both HF/HFr groups. The LET-treated group did not develop endocrine or metabolic abnormalities, but polycystic ovaries were seen. Since the HF/HFr diet can cause substantial metabolic and reproductive dysregulation in both LET-treated and placebo mice, food items rich in simple sugar—particularly fructose—and saturated fat, which have the potential to lead to PCOS progression, should be eliminated from the diet of young females.
This study aimed to assess the association between dietary factors and depression in a group of polycystic ovary syndrome (PCOS) women and to evaluate potential interactions and the mediating role of BMI in this relationship. One hundred and sixteen women with PCOS were asked to complete the Dietary Habits and Nutrition Beliefs Questionnaire and the manual for developing of nutritional data (KomPAN questionnaire) and the Beck Depression Inventory. The population was divided into two groups: (1) not at risk of depression (ND), n = 61, and (2) at risk of depression (RD), n = 55. Significantly higher BMI values were observed in the RD group than in the ND group. In the RD group, the intake of vegetables and legumes was lower than in the LD group, but the consumption of sweet beverages and energy drinks was higher. Consumption of vegetables and legumes at least twice per day is known to be associated with a 62% lower probability of the risk of depression in PCOS women. Furthermore, women with overweight and obesity have a 5.82 times greater chance of depression than women with normal body weight. Our findings show that there is a significant association between certain dietary factors, BMI, and symptoms of depression in PCOS women.
The aim of this study was to clarify the associations between menstrual cycle disorders, food frequency intake, dietary habits, and physical activity levels in women with and without Polycystic Ovary Syndrome (PCOS). 114 women with PCOS and 341 without PCOS (CONTROL) participated in the study. They were also divided into women with menstrual disorders(MD), and those with regular cycle (RC). Each of them completed a medical and Kompan questionnaires. In women with PCOS and menstrual disorders (PCOS-MD), intake of wholemeal products, meat and meat products, fats and alcoholic beverages was higher in comparison to those in the control group with menstrual disorders (CONTROL-MD). Women in the PCOS-MD group also reported significantly more frequent snacking between meals, higher Pro-Healthy Diet Index (pHDI-14), and a lower level of physical activity at leisure time than CONTROL-MD. Women with PCOS differed from those in CONTROL due to a higher consumption of meat and meat products, fats, fruits and vegetables, juices and alcoholic beverages, and a lower intake of whitemeal products, sweets, and fruits. Women with PCOS more frequently snacked, but the number of their meals was also lower. In women with PCOS, menstrual disorders may be related not only with diet quality and physical activity but also with snacking and skipping meals.
Background: Time-restricted eating (TRE) appears to be a promising dietary strategy for women with polyendocrine metabolic ovarian syndrome (PMOS), with potential benefits for insulin resistance and metabolic health. Emerging evidence also suggests that TRE may be associated with changes in gut microbiota composition and microbial metabolites, as well as circulating biomarkers involved in metabolic regulation. However, the relationships among these factors remain poorly understood. Objective: The aim of this study is to test the hypothesis that adding TRE to Healthy Eating Plate recommendations is more effective in improving insulin resistance, assessed using HOMA-IR, than Healthy Eating Plate recommendations alone in women with PMOS. Exploratory analyses will investigate changes in gut microbiota composition, microbial metabolites, and circulating concentrations of neuroactive compounds. Methods: This two-arm, parallel-group randomized controlled trial will compare 8-h TRE with unrestricted meal timing in women aged 18 to 40 years with PMOS and a BMI of 25–40 kg/m2 with a 1:1 allocation ratio. Both groups will receive Healthy Eating Plate-based dietary advice and attend four visits; the TRE protocol will be followed for 8 weeks. The primary outcome will be a change in HOMA-IR from baseline to week 8. We will also assess changes in glucose and lipid metabolism, circulating neuroactive compounds, including GABA and kisspeptin, anthropometric parameters, hormonal profile, composition and diversity of the microbiota and its metabolites. Discussion: We anticipate that this study will expand the limited evidence regarding TRE in women with PMOS and provide exploratory insights into the relationships among gut microbiota composition, microbial metabolites, circulating GABA and kisspeptin, and insulin resistance. The findings may help identify potential mechanisms underlying the metabolic effects of TRE in this population. Protocol version: 1.1, August 2026. Trial registration number: NCT06204965. Trial status: Participant recruitment has not yet commenced.